PolymarketCheck availabilityNo KYCVerified resolution dataWell calibratedCurrent implied probability
December 31, 67%Leader of 3 outcomes
December 31, 67%Market quality
63 / 100
Medium quality24h Volume
$309.5
Liquidity
$20.4K
Medium liquiditySpread
1.0 pt
Tight spreadComments
0
Market data
Updated 7 minutes ago
Aug 19, 26, 5:49 PM UTCJan 1, 28, 4:59 AM UTC
Trends
Venue terms
Source: Polymarket
Informational venue terms only; CoinRithm paper trading uses its own rules.
- Minimum order (shares):
- 5
- Tick size:
- 1 percentage points
- Fees:
- Yes
Related Markets
Related questions for context, not a comparison of equivalent contracts.
Is Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketWill the Russian cancer vaccine work?
Manifold MarketsFDA approves Retatrutide this year?
PolymarketFDA approves YCT-529 male birth control pill before 2035?
Manifold MarketsRules
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
